Oxford Biomedica
{{Short description|BioTech Company}}
{{EngvarB|date=September 2013}}
{{Use dmy dates|date=May 2024}}
{{Infobox company
| logo = Oxford Biomedica logo.jpg
| name = Oxford Biomedica plc
| type = Public company
| traded_as = {{ubl|{{LSE|OXB}}}}
| foundation = 1995
| location = Oxford
| key_people = Frank Mathias (CEO)
| num_employees =
| revenue = {{increase}} £128.8 million (2024){{cite web|url=https://oxb.com/wp-content/uploads/2025/04/Preliminary-results-for-the-year-ended-31-December-2024.pdf|title=Annual Results 2024|publisher=Oxford Biomedica|access-date=14 April 2025}}
| operating_income = {{increase}} £(39.4) million (2024)
| net_income = {{increase}} £(48.6) million (2024)
| industry = Pharmaceutical industry
| website = https://oxb.com/
}}
Oxford Biomedica (OXB) is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange.{{cite web|url=https://research.ftserussell.com/products/index-notices/home/getnotice/?id=2596588|title=FTSE UK Index Series: Annual Review June 2020|date=3 June 2020|access-date=3 June 2020|archive-date=3 June 2020|archive-url=https://web.archive.org/web/20200603233614/https://research.ftserussell.com/products/index-notices/home/getnotice/?id=2596588|url-status=dead}}
History
The company was established in 1995 as a spin out from the University of Oxford.[http://www.hoovers.com/oxford-biomedica/--ID__103385--/free-co-factsheet.xhtml Hoover's | A D&B Company]. Hoovers.com. It was the subject of an initial public offering on the Alternative Investment Market in 1996.{{cite book|url=https://books.google.com/books?id=EOXnCwAAQBAJ&dq=%22Oxford+BioMedica%22+ipo+aim+1996&pg=PA174|title=Science, the State and the City: Britain's Struggle to Succeed in Biotechnology|page=174|first1= Geoffrey|last1= Owen|first2=Michael M.|last2= Hopkins|publisher=Oxford University Press|year=2016|isbn= 978-0198728009}}
In 2018, OXBs gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences.{{cite web|title=Oxford Biomedica seals $842m Parkinson's therapy deal with Axovant
|url=https://www.ft.com/content/027f49c6-6970-11e8-b6eb-4acfcfb08c11|first1=Clive|last1=Cookson|work=Financial Times |date=6 June 2018|access-date=27 June 2018}}
In May 2019, the company announced an investment by Novo Holdings for a stake of 10.1% in OXB, totalling $55 million (USD) to develop its gene therapy technology.{{Cite web|url=https://www.labiotech.eu/medical/oxford-biomedica-novo-gene-therapy/|title=€60M Investment to Boost Oxford Biomedica's Gene and Cell Therapies|first=Jonathan|last= Smith|date=2019-05-29|website=Labiotech.eu|language=en-US|access-date=2020-03-13}} The firm had already established collaborations with Sanofi, Novartis and other groups to provide lentiviral vector manufacturing.{{Cite web|url=https://www.evaluate.com/vantage/articles/analysis/plenty-choice-remains-buyers-gene-therapy|title=Plenty of choice remains for buyers of gene therapy|date=2019-12-20|website=Evaluate.com|language=en|access-date=2020-03-26}}
In November 2019, Microsoft announced a partnership with OXB to improve the next generation of cell and gene delivery technology using the cloud and machine learning, contributing large data sets for analysis via the Microsoft Azure intelligent cloud platform to develop in-silico models and novel algorithms to help provide long-term and curative treatments for a wide range of diseases.{{Cite web|url=http://www.pharmatimes.com/magazine/2019/november_2019/transforming_the_landscape|title=Transforming the landscape|last=Rut|first=Andrew|date=2019-10-28|website=PharmaTimes|language=en|access-date=2020-03-04}}
In December 2019, the company announced that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio including five lentiviral vectors for CAR-T products, which builds on the existing three-year commercial supply agreement signed by the parties in July 2017.{{Cite web|url=https://www.thepharmaletter.com/article/oxford-biomedica-extends-lentiviral-deal-with-swiss-giant|title=Oxford Biomedica extends lentiviral deal with Swiss giant|website=Phara Letter|date=19 December 2019|access-date=3 June 2020}}
In April 2020, OXB announced that the company had joined a Consortium led by the Jenner Institute, Oxford University, to develop and manufacture a vaccine for COVID-19: ChAdOx1 nCov-19.{{cite web|url=https://fancycomma.com/2020/07/02/all-about-the-oxford-astrazeneca-covid19-vaccine/|title=Could the Oxford University/AstraZeneca COVID-19 Vaccine End the Pandemic?|date=2 July 2020|access-date=25 June 2020}} This is one of the vaccines currently being deployed under a conditional authorisation.{{cite web|url=http://www.pharmatimes.com/news/oxford_biomedica_joins_consortium_for_promising_covid-19_vaccine_1337937|title=Oxford Biomedica joins consortium for promising COVID-19 vaccine|date=8 April 2020|publisher=Pharma Times|access-date=3 June 2020}}{{cite news|url=https://www.fiercepharma.com/manufacturing/oxford-biomedica-earns-uk-nod-for-4th-manufacturing-suite-to-boost-covid-19|title=Oxford Biomedica earns U.K. nod for 4th manufacturing suite to boost COVID-19 production|date=6 October 2020|newspaper=Fierce Pharma|access-date=8 May 2021}}
In September 2023, it was announced OXB had acquired the Illkirch-Graffenstaden-headquartered, viral vectors drug product manufacturing services company, ABL Europe from the Mérieux Institute.{{Cite web |date=2023-09-28 |title=Oxford Biomedica acquires ABL Europe |url=https://thebusinessmagazine.co.uk/corporate-finance/oxford-biomedica-acquires-abl-europe/ |access-date=2023-09-28 |website=The Business Magazine |language=en-GB}}
References
{{Reflist}}
{{Pharmaceutical industry in the United Kingdom}}
{{Authority control}}
Category:Pharmaceutical companies
Category:Pharmaceutical companies of the United Kingdom
Category:Pharmaceutical companies established in 1995